FHTX Q2 2025 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

FHTXFoghorn Therapeutics Inc.

$330M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+9.7% YoY

Gross Profit

$7M88.1% margin

Operating Income

-$21M-279.2% margin

Net Income

-$18M-237.3% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

+27.0%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$226M

Total Liabilities

$303M

Stockholders' Equity

-$77M

Cash & Equivalents

$73M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$7M	+9.7%
Gross Profit	$7M	$7M	-3.4%
Operating Income	-$21M	-$27M	+20.8%
Net Income	-$18M	-$23M	+21.9%